Abstract
cells, and in other tissues such as adult thymic medulla, cornea, nail matrix, pancreatic islets, erythroid and endothelial precursors, and mesenchymal stem cells
. Importantly, an increasing number of studies have highlighted its clinical relevance in certain pathological conditions, such as oncology, autoimmunity, inflammation, infection and transplantation [8] . In the context of tumour biology, since Paul et al. [16] described the expression of HLA-G in melanoma for the first time, augmented HLA-G expression in situ was observed nearly in 20 types of tumours [17] . HLA-G was preferentially detected in tumour tissue and rarely in the adjacent normal tissue, suggesting its specific association with tumour growth and progression. Aberrant expression of HLA-G in cancer has been implicated both in establishment of anti-tumour immune responses and in tumour evasion which was involved in three essential phases of cancer immunoediting procession: elimination, equilibrium and escape [18] [19] . [20, 21] . Furthermore, changes in the level of sHLA-G have been detected from patients with solid tumours and lymphoproliferative disorders. However, the clinical relevance of sHLA-G in malignancies remains to be explored. For example, high sHLA-G level is significantly correlated with survival in glioblastoma multiforme but does not appear to be predictive of survival in neuroblastoma [22, 23] . [24] . Pathologic stage was based on the revised international system [25] (Fig. 1A) . [27] . Here, HLA-G expression in partial samples was test by Western blot. Our data showed that immunohistochemistry results were highly consistent with that of the Western blot analysis (Fig. 1B) . (Fig. 2A) .
. However, the exact time-point of HLA-G expression in tumour cells remains elusive. Generally, tumour cells are genetically instable, so the activation of HLA-G could take all the way during the tumour formation and development. HLA-G during chronic inflammation would enable the growth of transformed cell beyond recognition of host immunosurveillance. This was supported by the findings that an increased risk for the development of malignancy was observed in the setting of inflammatory conditions of the gut, such as ulcerative colitis and Crohn's disease

HLA-G expression induced by microenvironment cues including cytokines in these conditions might be involved in the anti-inflammation immune responses and malignant transformation
To date, little information was available for the clinical relevance of HLA-G, particularly, both the primary lesion HLA-G expression and patient plasma sHLA-G, in lung cancer. In an effort to gain further insight into the roles of HLA-G in NCSLC, both HLA-G expression in primary lesions and plasma sHLA-G from non-small-cell lung cancer (NSCLC) patients were analysed, and their correlation to clinical parameters were evaluated. Furthermore, functions of the transfected HLA-G cell surface expression in lung cancer cell line A549 and plasma sHLA-G from NSCLC patients on NK cell cytolysis were also determined.
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HLA-G expression in primary NSCLC lesions
Specificity of the antibodies for detecting HLA-G raises concerns as Apps et al. mentioned
Plasma sHLA-G expression in NSCLC patients
HLA-G expression in NSCLC relative to clinicopathological parameters
HLA-G expression was observed in 32.35% (11/34) (Fig. 2B) . (Fig. 3A) . However, for the lesion HLA-G expression, no statistical significance was reached for the survival analysis (P ϭ 0.498) (Fig. 3B) . (Fig. 5A, B) . No sHLA-G was detected in the A549-G cells with ELISA, Western blot and immunocytochemistry (Fig. S1) , and flow cytometry (Fig. 5B, C) . These data Fig. 4, plasmas Fig. 5C ), which could also be restored partially by the functional HLA-G specific antibody 87G in a manner of dosage dependent (Fig. 5D) . [29, 30] . In the scenario of NSCLC, the ratio of down-regulation of HLA class I expression varies widely from 25% to 90% among different studies [31] [32] [33] [34] , and the clinical relevance of HLA class I expression status in disease prognosis remains controversial [32, 34] . Be noted, expression of HLA class I antigens is not always associated with the susceptibility of tumour cells to CTL lysis which is partially due to the lack of TA-derived peptide presentation by a given HLA class I allospecificity [35] . But when [18] . In addition to HLA-G expression in situ, sHLA-G molecules have been found circulating at high concentrations in certain cancer patients including glioblastoma multiforme, breast and ovarian cancers, lymphoblastic and monocytic acute leukaemia, malignant melanoma and neuroblastoma [7, 23, 37, 38] [38, 48, 49] . The latter mechanism was indicated by the induction of in vitro sHLA-G production by monocytes following incubation with tumour-cell-derived supernatants [50] . Given 
Inhibition of NK-92 cytolysis against A549 cells by both plasma sHLA-G and cell surface HLA-G in vitro
Fig. 3 Kaplan-Meier estimates the survival curves for NSCLC patients with HLA-G expression in primary lesions (n ϭ 51) or plasma sHLA-G (n ϭ 67). (A) Patients with the sHLA-G above median level (32.0 U/ml) had a significantly shorter survival time than that with lower sHLA-G expression (P ϭ 0.044). (B) No statistical significance was observed for the HLA-G expression in primary lesions and survival (P ϭ 0.498). suggested that only the cell surface HLA-G1 was expressed in A549-G cells. Cytotoxic effector cells were then challenged with target lung cancer A549 cells by the LDH release assay. As shown in
Discussion
At the beginning of primary tumours expansion, the cells are less invasive and metastatic. During cancer immune editing, host immune system plays in eliminating tumour cells and in facilitating the emergence of their immunoresistant variants. Due to genetic alterations present in each cancer cell, metastatic cells acquire particular genetic, phenotypic and biological characteristics that are not present in the primary tumours [1]. Among these alterations, partially or totally down-regulate the expression of MHC class I antigens is one of the most common events in the tumour progression. A variety of altered
HLA class I-defective tumour variants appear, T-cells cannot recognize these targets, and these tumour clones acquire a growth advantage that allows them to take over the other clonal tumour populations with the expression of immunosuppressive molecules such as HLA-G [36]. Since the first address of HLA-G expression by tumour cells in 1998, numerous studies have been performed and HLA-G in situ expression was observed in various malignancies such as colorectal cancer, retinoblastoma, ovarian carcinoma, breast carcinoma, haematopoietic tumours, renal cell carcinoma and lung cancer
(B) Flow cytometry analysis of cell surface HLA-G expression on A549 cells (a) and A549-G cells (b) with mAb MEM-G/9; intracellular sHLA-G staining in A549-G cells with mAb 2A12 (c). (C) Comparison of the mean cytolytic percentage of NK-92 to A549 and A549-G. (D)
Supporting Information
Additional Supporting Information may be found in the online version of this article: Fig. S1. Analysis of sHLA-G 
